Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

May

Today In Oncology

Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer PROs in TOPAZ-1

Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer

Local Recurrence of Endometrial Cancer Radiotherapy With or Without Cisplatin

Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers

Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes

Opening Session Panel Discussion

Related Videos